Literature DB >> 7729638

Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection.

G Marinos1, N V Naoumov, S Rossol, F Torre, P Y Wong, H Gallati, B Portmann, R Williams.   

Abstract

BACKGROUND/AIMS: Patients with chronic hepatitis B infection have elevated plasma tumor necrosis factor (TNF) alpha levels. Two TNF-alpha receptors have been identified, each responsible for distinct TNF-alpha activities. The aim of this study was to evaluate the biological function of the elevated TNF-alpha in chronic hepatitis B virus infection by examining the two TNF signaling pathways in the evolution of hepatitis B-related liver injury.
METHODS: The hepatic expression of the two TNF receptors and the corresponding serum levels of the soluble forms of both TNF receptors were determined and correlated with hepatic inflammation and virus replication in 98 chronic hepatitis B surface antigen carriers. Forty hepatitis B e antigen-positive patients were also studied prospectively, while on interferon alfa treatment, to examine the TNF receptor response during viral clearance.
RESULTS: In chronic hepatitis B virus infection, the hepatic expression and serum levels of TNF receptors, in particular 75-kilodalton TNF receptor subtype (TNF-R p75), are significantly enhanced in association with hepatic inflammation and hepatocytolysis but not with hepatitis B virus replication. During interferon alfa treatment, a significant increase of soluble TNF-R p75 always precedes the hepatitis B e antigen antibody against hepatitis B e antigen seroconversion in responders to treatment.
CONCLUSIONS: In chronic active hepatitis B infection, there is an up-regulation of the TNF receptor system, preferentially the TNF-R p75 signaling pathway, which suggests that the TNF-alpha/TNF receptor system has an important role in the pathogenesis of liver damage and viral clearance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729638     DOI: 10.1016/0016-5085(95)90694-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  22 in total

1.  Immunological changes of mild acute pancreatitis in late-stage alcoholic chronic pancreatitis.

Authors:  C Hanck; S Rossol; M V Singer
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

2.  Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.

Authors:  F Torre; S Rossol; N Pelli; M Basso; A Delfino; A Picciotto
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

3.  Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus.

Authors:  Gregor Ebert; Simon Preston; Cody Allison; James Cooney; Jesse G Toe; Michael D Stutz; Samar Ojaimi; Hamish W Scott; Nikola Baschuk; Ueli Nachbur; Joseph Torresi; Ruth Chin; Danielle Colledge; Xin Li; Nadia Warner; Peter Revill; Scott Bowden; John Silke; C Glenn Begley; Marc Pellegrini
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-20       Impact factor: 11.205

Review 4.  Infliximab-related hepatitis: a case study and literature review.

Authors:  Francisco Colina; Aída Molero; Begoña Casís; Pilar Martínez-Montiel
Journal:  Dig Dis Sci       Date:  2013-05-05       Impact factor: 3.199

5.  Association between TRAIL expression on peripheral blood lymphocytes and liver damage in chronic hepatitis B.

Authors:  Gong-Ying Chen; Jian-Qin He; Guo-Cai Lu; Ming-Wei Li; Chen-Huai Xu; Wei-Wei Fan; Chen Zhou; Zhi Chen
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

6.  Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection.

Authors:  B Kallinowski; K Haseroth; G Marinos; C Hanck; W Stremmel; L Theilmann; M V Singer; S Rossol
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

Review 7.  The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.

Authors:  G Kollias; E Douni; G Kassiotis; D Kontoyiannis
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

8.  Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin.

Authors:  E Redondo-Cerezo; F Casado-Caballero; J L Martin-Rodriguez; J Hernandez-Quero; F Escobar-Jimenez; J L Gonzalez-Calvin
Journal:  Osteoporos Int       Date:  2014-03-28       Impact factor: 4.507

Review 9.  Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.

Authors:  L H Calabrese; N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

10.  Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design.

Authors:  Nancy Gasper-Smith; Deanna M Crossman; John F Whitesides; Nadia Mensali; Janet S Ottinger; Steven G Plonk; M Anthony Moody; Guido Ferrari; Kent J Weinhold; Sara E Miller; Charles F Reich; Li Qin; Stephen G Self; George M Shaw; Thomas N Denny; Laura E Jones; David S Pisetsky; Barton F Haynes
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.